Treatment of palmoplantar psoriasis with monochromatic excimer light (308-nm) versus cream PUVA.
Palmoplantar psoriasis is a chronic disease, which is very resistant to treatment and often leads to severe disabilities. Photochemotherapy employing psoralens combined with UVA irradiation (PUVA) is a well-accepted therapy for palmoplantar psoriasis. Its topical application (bath PUVA; cream PUVA) avoids the typical side effects of orally applied psoralens. We compared the efficacy of cream PUVA therapy with monochromatic excimer light therapy, a treatment modality employing 308-nm UVB radiation generated by a new kind of light source. Ten patients with psoriasis of the palms and soles were randomly assigned to receive cream PUVA on one side and 308-nm UVB on the contralateral side. Based on the psoriasis area and severity index (PASI) score, clinical assessment was carried out before and 5 weeks after the beginning of the study. At the end of the treatment period both test groups showed a remarkable PASI score reduction (308-nm UVB, 63.57%; cream PUVA, 64.64%). No relevant adverse effects were observed, except for mild irritation in a few patients. After a 12-week follow-up, a relapse of the disease was only observed in one patient. Thus, mono-chromatic excimer light cleared palmoplantar psoriasis as rapidly as cream PUVA. In contrast to cream PUVA, monochromatic excimer light therapy is not associated with prior drug application. This might lead to a lower incidence of adverse reactions and better compliance. Therefore, monochromatic excimer light therapy seems to be a useful new therapeutic option for palmoplantar psoriasis.
Department of Dermatology, Heinrich-Heine-University Duesseldorf, Germany. neumannt@uni-duesseldorf.de
Norbert J
NJ
Neumann
Natalia
N
Mahnke
Dorothea
D
Korpusik
Helger
H
Stege
Thomas
T
Ruzicka
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D005363:Ficusin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011701:PUVA Therapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011565:Psoriasis / Q000628:therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods*
D009824:Ointments; D017319:Photosensitizing Agents; D005363:Ficusin